About
About
About
About
Code Pharma has been an established scientific research company with knowledgeable and experienced staff, committed and dedicated in the field of viral infections, AIDS and Cancer research.
We aim to bring to the market a cost-effective treatment based on findings from extensive research to the entire target demographic irrelevant of income or status.
Our ground-breaking research and patent protected findings are the basis of a new era of fighting against infectious and oncological diseases.
Code Pharma
About
Code Pharma has been an established scientific research company with knowledgeable and experienced staff, committed and dedicated in the field of viral infections, AIDS and Cancer research.
We aim to bring to the market a cost-effective treatment based on findings from extensive research to the entire target demographic irrelevant of income or status.
Our ground-breaking research and patent protected findings are the basis of a new era of fighting against infectious and oncological diseases.
Code Pharma
About
Code Pharma has been an established scientific research company with knowledgeable and experienced staff, committed and dedicated in the field of viral infections, AIDS and Cancer research.
We aim to bring to the market a cost-effective treatment based on findings from extensive research to the entire target demographic irrelevant of income or status.
Our ground-breaking research and patent protected findings are the basis of a new era of fighting against infectious and oncological diseases.
Code Pharma
About
Code Pharma has been an established scientific research company with knowledgeable and experienced staff, committed and dedicated in the field of viral infections, AIDS and Cancer research.
We aim to bring to the market a cost-effective treatment based on findings from extensive research to the entire target demographic irrelevant of income or status.
Our ground-breaking research and patent protected findings are the basis of a new era of fighting against infectious and oncological diseases.
Code Pharma
About
Code Pharma has been an established scientific research company with knowledgeable and experienced staff, committed and dedicated in the field of viral infections, AIDS and Cancer research.
We aim to bring to the market a cost-effective treatment based on findings from extensive research to the entire target demographic irrelevant of income or status.
Our ground-breaking research and patent protected findings are the basis of a new era of fighting against infectious and oncological diseases.
Code Pharma
About
Code Pharma has been an established scientific research company with knowledgeable and experienced staff, committed and dedicated in the field of viral infections, AIDS and Cancer research.
We aim to bring to the market a cost-effective treatment based on findings from extensive research to the entire target demographic irrelevant of income or status.
Our ground-breaking research and patent protected findings are the basis of a new era of fighting against infectious and oncological diseases.
Code Pharma
Jerusalem Post
This September, we were featured in the Jerusalem Post, Israel’s most read English newspaper. The publication reviews our clinical trials, the promising results, and the impact Codivir may have on the global pandemic. Read the full article here:
Global Trend Monitor
We were featured in the Global Trend Monitor, a UAE-based business & lifestyle magazine!
Read the interview with our founder & CEO Zyon Ayni and find out how Zyon founded Code Pharma to develop ground-breaking medical solutions as well as the promising results of our clinical trials regarding Codivir, its safety and effectiveness.
Gulf Today
Read the latest feature of Code Pharma in Gulf Today and find out how Codivir was discovered, our successful Phase I results, and where we stand with the Phase II study and emergency approvals from several countries
Code Pharma announces limited fundraising round for internators
We're going for an IPO and are launching a limited fundraising round for professional investors! Please find all the necessary information in our latest press release